ELF promotes new discoveries
through open innovation and crowdsourcing

The European Lead Factory is a unique public-private partnership working to deliver innovative drug discovery starting points via open innovation and crowdsourcing. The European Lead Factory was established in 2013, when several pharmaceutical companies, universities and small- and medium-sized enterprises (SMEs) joined forces to create a high-quality compound library, and screening infrastructure referred to as the European Screening Centre. Combining the best of several worlds – the expertise, experience and state-of-the-art techniques of industry; the innovative strength of academic institutions; and the agility and creativity of SMEs – the ultimate goal of the ELF has been to boost early drug discovery and seed new hit-to-lead programmes.

Assets of the European Lead Factory

As of 2019, the current ELF compound library consists of approximately 535,000 compounds. This includes >350,000 EFPIA compounds, supplemented by around approximately 190,000 compounds of the Public Compound Collection, developed by leading chemistry SMEs and academic groups. The European Screening Centre harbours skilled experts in the field of assay development, Ultra-High-Throughput & High Content Screening, hit finding, and compound logistics, while our four participating medicinal chemistry SMEs take care of the resynthesis activities for reconfirmation. Finally, a bespoke informatics system, the Honest Data Broker, has been developed to help manage the intellectual property of the contributed assets to enable the development of resulting leads.

Achievements to date:

Since 2013, more than 200 drug discovery programmes have been run at the ELF. These high-quality programmes have led to a balanced portfolio of innovative disease targets, the results of which are increasingly being made public, indicating the long-lasting impact that the ELF can generate.

Over 100 publications have come out of ELF collaborations and more than 20 programmes are now available for partnering. Spin-off companies Scandicure and Keapstone Therapeutics were created based on work performed at the ELF, and most recently, the ELF has helped identify two drug candidates for cancer treatment that have now progressed to phase 1 clinical trial testing. Furthermore, work at the ELF has contributed to the discovery of a new class of drug that has the potential to reverse antibiotic resistance for conditions such as pneumonia and sepsis.

The various testimonials of ELF partners and collaborators give a taste of how the partnership has helped push their work forward. A comprehensive overview of the impact of the ELF was recently published in Nature Reviews Drug Discovery.

Looking ahead

As of February 2022, the ELF has closed its open calls for screening proposals. The partnership aims to continue its efforts and is actively working to achieve sustained funding to reopen regular calls for proposals in the future.
Previously only open to European researchers eligible for IMI funding, the European Lead Factory (ELF) is now, for the first time, offering its services to charities and foundations around the world, through charity funded screens.
With this move, the ELF and partners will:

• Make the ELF assets and infrastructure open and accessible to the larger drug discovery community
• Add to global health and well-being by leveraging partnering opportunities in Europe and beyond
• Explore uncharted biological territory through the sourcing of new targets, pathways, and phenotypes to address unmet medical needs